" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions

Published: Tuesday, August 31, 2010
Last Updated: Tuesday, August 31, 2010
Bookmark and Share
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.

Lonza enters the viral based-manufacturing market with its purchase of Vivante GMP Solutions, Inc. The acquisition advances Lonza’s strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets.

Based in Houston, Texas, Vivante is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics. The company’s viral-vaccine production services will be enhanced by Lonza’s established expertise in expression technologies and large-scale manufacturing platforms.

Additionally, Vivante’s experience with pre-clinical through late-stage supply of viral vector-based products will compliment Lonza’s growing cellular and gene therapy process development and manufacturing capabilities.

“Lonza is strategically committed to being successful in the growing viral marketplace. Vivante’s expertise will allow us to accelerate our entry into the viral-based manufacturing arena”, said David Smith, Lonza’s Head of Therapeutic Cell Solutions.

J. David Enloe Jr., Vivante’s founder, president and CEO, added, “We could not be happier with the opportunity to be at the forefront of Lonza’s expansion into the viral vaccine and vector market. We believe that the combination of Vivante’s expertise with the technical know-how, financial resources, and global reach that Lonza offers will be a tremendous advantage for our clients, both present and future.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza to Build Capabilities for Drug Product Development
Company to Develop Drug Product Services for Customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza to Build Capabilities for Drug Product Development Services
Lonza is entering the field of Drug Product Development Services for customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza and Benitec Enter Agreement
Agreement to develop scalable AAV manufacturing process for ddRNAi therapeutics.
Friday, October 09, 2015
Lonza and CytoMate Collaboration on CytoSMART™ Technology
Agreement for global distribution of the new technology which is designed for easy, affordable live cell imaging.
Thursday, March 05, 2015
Lonza and arGEN-X Announces Commercial License Agreement
A multi-product GS Xceed™ license agreement for the production of therapeutic antibodies.
Friday, February 20, 2015
Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!